Ascendis nears EU achondroplasia launch as Yorvipath lifts product sales 89%
Third-quarter product revenue reached €366m with an operating profit of €125m, while European regulators backed TransCon CNP, setting up a possible German launch in early 2027.
Ascendis Pharma has reported third-quarter 2026 product revenue of €366m, up 89% on the year, and an operating profit of €125m. The figures were published on 12 November.
Yorvipath accounted for €291m, or roughly four-fifths of the total, so the quarter's growth rests largely on a single product. Skytrofa and Yuviwel, the latter newly launched, also added to sales, though the company's summary gave no separate figures for them.
The nearer-term commercial question is TransCon CNP in paediatric achondroplasia. The European Medicines Agency's human-medicines committee, the CHMP, has adopted a positive opinion. Its orphan-drug committee, the COMP, separately backed keeping the product's orphan designation. The two bodies assess different questions: the CHMP weighs benefit and risk, while the COMP looks at orphan status.
Ascendis expects the European Commission to issue its decision in the fourth quarter of 2026. As general context, the Commission usually follows a CHMP opinion when it issues the legally binding authorisation. The company plans to launch first in Germany in the first quarter of 2027.
The company also pointed to infant Week 52 data for the programme and said pivotal topline data are expected in the third quarter of 2027.
Why it matters
- Yorvipath supplied about 80% of product revenue in the quarter, so Ascendis's near-term sales growth depends heavily on that one product.
- The Commission decision expected in Q4 2026 is the step that would turn the CHMP's positive opinion into a marketing authorisation for TransCon CNP.
- Orphan designation, if retained, bears on how the product is positioned in paediatric achondroplasia.
- A German launch planned for Q1 2027 sets the timetable for national pricing and reimbursement work, with pivotal topline data due in Q3 2027.
Company's press release (SEC filing): Ascendis Pharma A/S ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
